Next Article in Journal
Predictors of Sexual Dysfunction in Veterans with Post-Traumatic Stress Disorder
Previous Article in Journal
HIV and cART-Associated Dyslipidemia Among HIV-Infected Children
Article Menu

Export Article

Open AccessArticle
J. Clin. Med. 2019, 8(4), 431;

Inhibition of Osteoclastogenesis by Thioredoxin-Interacting Protein-Derived Peptide (TN13)

Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Yuseong-gu, Daejeon 34141, Korea
Department of Biochemistry, School of Life Sciences, Chungbuk National University, Cheongju 28644, Korea
Department of Functional Genomics, University of Science and Technology, Yuseong-gu, Daejeon 34113, Korea
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 21 February 2019 / Revised: 22 March 2019 / Accepted: 27 March 2019 / Published: 29 March 2019
(This article belongs to the Special Issue Pain in Osteoporosis: From Pathophysiology to a Therapeutic Approach)
PDF [1796 KB, uploaded 29 March 2019]
  |     |  


Overactivated osteoclasts lead to many bone diseases, including osteoporosis and rheumatoid arthritis. The p38 MAPK (p38) is an essential regulator of the receptor activator of nuclear factor-κB ligand (RANKL)-mediated osteoclastogenesis and bone loss. We previously reported TAT conjugated thioredoxin-interacting protein-derived peptide (TAT-TN13) as an inhibitor of p38 in hematopoietic stem cells (HSCs). Here, we examined the role of TAT-TN13 in the differentiation and function of osteoclasts. TAT-TN13 significantly suppressed RANKL-mediated differentiation of RAW 264.7 cells and bone marrow macrophages (BMMs) into osteoclasts. TAT-TN13 also inhibited the RANKL-induced activation of NF-κB and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), leading to the decreased expression of osteoclast-specific genes, including tartrate-resistant acid phosphatase (TRAP) and Cathepsin K. Additionally, TAT-TN13 treatment protected bone loss in ovariectomized (OVX) mice. Taken together, these results suggest that TAT-TN13 inhibits osteoclast differentiation by regulating the p38 and NF-κB signaling pathway; thus, it may be a useful agent for preventing or treating osteoporosis. View Full-Text
Keywords: osteoporosis; osteoclast; osteoclastogenesis; p38 MAPK; TAT-TN13; ovariectomy osteoporosis; osteoclast; osteoclastogenesis; p38 MAPK; TAT-TN13; ovariectomy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Kim, M.J.; Kim, W.S.; Byun, J.-E.; Choi, J.H.; Yoon, S.R.; Choi, I.; Jung, H. Inhibition of Osteoclastogenesis by Thioredoxin-Interacting Protein-Derived Peptide (TN13). J. Clin. Med. 2019, 8, 431.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top